Keratitis - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Keratitis - Pipeline Review, H2 2018’, provides an overview of the Keratitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Keratitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Keratitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Keratitis

- The report reviews pipeline therapeutics for Keratitis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Keratitis therapeutics and enlists all their major and minor projects

- The report assesses Keratitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Keratitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Keratitis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Keratitis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Editas Medicine Inc

EyeGate Pharmaceuticals Inc

MimeTech Srl

NanoViricides Inc

RegeneRx Biopharmaceuticals Inc

SIFI SpA

Editas Medicine Inc

EyeGate Pharmaceuticals Inc

MimeTech Srl

NanoViricides Inc

RegeneRx Biopharmaceuticals Inc

SIFI SpA

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Keratitis - Overview

Keratitis - Therapeutics Development

Pipeline Overview

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Keratitis - Overview

Keratitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Keratitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Keratitis - Companies Involved in Therapeutics Development

Editas Medicine Inc

EyeGate Pharmaceuticals Inc

MimeTech Srl

NanoViricides Inc

RegeneRx Biopharmaceuticals Inc

SIFI SpA

Keratitis - Drug Profiles

acyclovir sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

B-2088 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ethamsylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Herpetic Keratitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IBN-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IVMED-90 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JDE-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KU-55933 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-8 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PIM-45 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polihexanide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RGN-259 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Herpetic Keratitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit DNA Synthesis for Herpetic Keratitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

targocil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VBP-245 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Z-9445 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Keratitis - Dormant Projects

Keratitis - Discontinued Products

Keratitis - Product Development Milestones

Featured News & Press Releases

Oct 13, 2017: ODAK Project: Phase III Clinical Trial is ready to start in Italy

Jun 01, 2016: RegeneRx and Lee's Pharm Announce Acceleration of RGN-259 Development in China

May 27, 2016: SIFI announces the conclusion of Phase I clinical trial for the development of PHMB an orphan drug for the treatment of Acanthamoeba Keratitis, a rare ocular disease

Jan 12, 2016: NanoViricides CEO Dr. Eugene Seymour to Present at the Biotech Showcase in San Francisco on Wednesday

Oct 21, 2015: RegeneRx Updates on U.S. Ophthalmic Clinical Trials

Sep 30, 2015: RegeneRx Receives $500,000 Milestone Payment With Enrollment of First Patient in U.S. Phase 2b/3 Dry Eye Trial

Sep 21, 2015: RegeneRx Announces First Patient Enrolled in Phase 3 U.S. Neurotrophic Keratopathy Clinical Trial with RGN-259

Oct 20, 2014: RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Keratitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under ...

List of Tables

Number of Products under Development for Keratitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Keratitis - Pipeline by Editas Medicine Inc, H2 2018

Keratitis - Pipeline by EyeGate Pharmaceuticals Inc, H2 2018

Keratitis - Pipeline by MimeTech Srl, H2 2018

Keratitis - Pipeline by NanoViricides Inc, H2 2018

Keratitis - Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2018

Keratitis - Pipeline by SIFI SpA, H2 2018

Keratitis - Dormant Projects, H2 2018

Keratitis - Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Keratitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by ...

List of Figures

Number of Products under Development for Keratitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports